Диссертация (1174357), страница 24
Текст из файла (страница 24)
– 2011. – Vol. 72 (1). – P. 10-14.149. Complex hyperplasia with and without atypia clinical outcomes andimplications of progestin therapy / S. D. Reed [et al.] // Obstet. Gynecol. – 2010. – Vol.116 (2 Pt. 1). – P. 365-373.150. Contemporary clinical management of endometrial cancer / H.E. Dinkelspiel[et al.] // Obstet. Gynecol. Int. – 2013. – Vol.
2013. – ID 583891.151. Coordinate regulation of estrogen-mediated fibronectin matrix assembly andEPF receptor transactivation by the G-protein-coupled receptor, GPR30 / J.A. Quinn [etal.] // Mol. Endocrinol. – 2009. – Vol. 23 (7). – P. 1052-1064.152. Correlations in the cytokine system in endometrial hyperplasia / A.V.Zhdanov [et al.] // Bull.
Exp. Biol. Med. – 2003. – Vol. 136 (3). – P. 270-272.153. Cunha, G.R. Role of stromal-epithelial interactions in hormonal responses /G.R. Cunha, P.S. Cooke, T. Kurita // Arch. Histol. Cytol. – 2004. – Vol. 67 (5). – P.417-434.154. CYP17 genetic polymorphism in patients with endometrial hyperplasia andcancer / M. Aban [et al.] // Int. J. Gynecol. Cancer. – 2006. – Vol. 16 Suppl 1. – P. 448451.155. Deligdisch, L. Hormonal pathology of the endometrium / L. Deligdisch //Mod. Pathol. – 2000.
– Vol. 13 (3). – P. 285-294.156. De Lignieres, B. Oral micronized progesterone / B. de Lignieres // Clin.Ther. – 1999. – Vol. 21 (1). – P. 41-58.154157. DeltaN-p53, a natural isoform of p53 lacking the first transactivationdomain, counteracts growth suppression by wild-type p53 / S. Courtois [et al.] //Oncogene.
– 2002. – Vol. 21 (44). – P. 6722–6728.158. Differential gene regulation by the two progesterone receptor isoforms inhuman breast cancer cells / J.K.Richer [et al.] // J. Biol. Chem. – 2002. – Vol. 277 (7). –P. 5209–5218.159. Donnez, J. Today’s treatments: medical, surgical and in partnership / J.Donnez // Int. J. Gynaecol. Obstet. – 1999. – 64 Suppl 1. – P. 5-13.160. Down-regulated progesterone receptor A and B coinciding with successfultreatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterinesystem / A.
Orbo [et al.] // Acta. Obstet. Gynecol. Scand. – 2010. – Vol. 89 (11). – P.1438-1446.161. Eichner, E. Endometrial hyperplasia treated by progestins / E. Eichner, M.Abellera // Obstet. Gynecol. – 1971. – Vol. 38. – P. 739-742.162. Effect of demographic factors on brachytherapy treatment results in patientswith endometrial cancer 1995-2010 / M.U. Jurczyk [et al.] // Ann. Agric.
Environ. Med.– 2013. – Vol. 20 (4). – P. 849-853.163. Effects of deprivation and replacement by percutaneous 17 beta estradiol andoral progesterone on blood pressure and metabolic parameters in menopause patientswith non-insulin-dependent diabetes / H. Mosnier-Pudar [et al.] // Arch. Mal. CoeurVaiss. – 1991. – Vol. 84 (8). – P.
1111-1115.164. Effects of estrogen or estrogen/progestin regimens on heart disease riskfactors in postmenopausal women / The Writing Group for the PostmenopausalEstrogen/Progestin Interventions (PEPI) Trial. // J. Am. Med. Assoc. – 1995 – Vol. 273(3). – P. 199-208.165. Effects of hormone replacement therapy on endometrial histology inpostmenopausal women : the Postmenopausal Estrogen / Progestin Interventions (PEPI)Trial // J. Am. Med.
Assoc. – 1996. – Vol. 275. – P. 370–375.166. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate onglandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors155(ER-a and ER-β) in human endometrial hyperplasia / A. B. Vereide [et al.] // Gynecol.Oncology. – 2006. – Vol. 101 (2). – P. 214 – 223.167. Effects of hormone replacement therapy on endometrial histology inpostmenopausal women.
The Postmenopausal Estrogen/Progestin Interventions (PEPI)Trial / The Writing Group for the PEPI Trial // JAMA 1996. – Vol. 275 (5). – P. 370375.168. Effects of oral and transdermal estrogen/progesterone regimens on bloodcoagulation and fibrinolysis in postmenopausal women / P.Y. Scarabin [et al.] //Arterioscler. Thromb. Vase. Biol. – 1997. – Vol. 17. – P. 3071–3078.169. Effect of postmenopausal hormone therapy on body weight and waist andhip girths.
Postmenopausal Estrogen-Progestin Interventions Study Investigators / M. A.Espeland [et al.] // J. Clin. Endocrinol. Metab. – 1997. – Vol. 82 (5). – P. 1549-1556.170. Effects of tamoxifen onuterus and ovaries of postmenopausal women in arandomised breast cancer prevention trial / R.P. Kedar [et al.] // Lancet.
– 1994. – Vol.343 (8909). – P. 1318-1321.171. Elliott, P.M. Cytosol oestradiol and progesterone receptors in endometrialhyperplasia and adenocarcinoma: determination by single saturating dose exchangeassays / P.M. Elliott, Z. Krozowski, R.P. Jansen // Aust. N. Z. J.
Obstet. Gynaecol. –1980. – Vol. 20 (4). – P. 199-204.172. Emarh, M. Cyclic versus continuous medroxyprogesterone acetate fortreatment of endometrialhyperplasia without atypia: a 2-year observational study / M.Emarh // Arch. Gynecol. Obstet. – 2015. – Vol. 292 (6). – P. 1339-1343.173. Endometrial cancer survival after breast cancer in relation to tamoxifentreatment: pooled results from three countries / M.E. Jones [et al.] // Breast Cancer Res.– 2012. – Vol. 14 (3).
– P. 91.174. Endometrial patterns and endocrinologic characteristics of asymptomaticmenopausal women / K. Gol [et al.] // Gynecol. Endocrinol. – 2001. – Vol. 15. – P. 6367.156175. Endometrial polyps in pre-and postmenopausal women: factors associatedwith malignancy / A. Jr.
Antunes [et al.] // Maturitas. – 2007. – Vol. 57(4). – P. 415421.176. Endometrial safety after 5 years of continuous combined transdermalestrogen and intrauterine levonorgestrel delivery for postmenopausal hormonesubstitution / D. Wildemeersch [et al.] Maturitas. – 2007. – Vol. 57 (2). – P. 205-209.177. Epithelial progesterone receptor exhibits pleiotropic roles in uterinedevelopment and function / H.L. Franco [et al.] // FASEB J.
– 2012 – Vol. 26 (3). – P.1218–1227.178. Estradiol attenuates EGF-induced rapid uPAR mobilization and cellmigration via the G-protein-coupled receptor 30 in ovarian cancer cells / E.Henic [et al.]// Int. J. Gynecol. Cancer. – 2009. – Vol. 19 (2). – P. 214-222.179. Estrogen and progesterone receptor expression in endometrial polyps/ K.Mittal [et al.] // Int. J. Gynecol. Pathol.
– 1996. – Vol. 15 (4). – P. 345-348.180. Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed inuterine endometrium and endometriotic lesions of patients with endometriosis / G.Hudelist [et al.] // Fertil. Steril. – 2005. – Vol. 84, Suppl. 2. – P. 1249-1256.181. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistancein endometriosis / S.E. Bulun [et al.] // Semin. Reprod. Med. – 2010. – Vol. 28 (1).
– P.36-43.182. Estrogen receptor beta (ERβ) in endometrial simple hyperplasia andendometrioid carcinoma / D. Chakravarty // Appl. Immunohistochem. Mol. Morphol. –2008. – Vol. 16 (6). – P. 535-542.183. Estrogenic GPR30 signalling induces proliferation and migration of breastcancer cells through CTGF / D.P.Pandey [et al.] // EMBO J. – 2009. – Vol. 28 (5). – P.523-532.184. Estrogens, MSI and Lynch syndrome-associated tumors / Ferreira A.M. [etal.] // Biochim. Biophys.
Acta. – 2009. – Vol. 1796 (2). – P. 194-200.157185. Evaluation of endometrium by transvaginal ultrasonography and Doppler intamoxifen-treated women with breast cancer / I. Bezircioglu [et al.] // European Journalof Gynaecological Oncology. – 2012.
– Vol. 33 (3). – P. 295–299.186. Evaluation of genomic imbalance in endometrial hyperplasia and carcinoma/ M. Bednarek [et al.] // Ginekol. Pol. – 2014. – Vol. 85 (11). – P. 828-832.187. Evaluation of mRNA expression of estrogen receptor beta and its isoformsin human normal and neoplastic endometrium / M.
Skrzypczak [et al.] // Int. J. Cancer.– 2004. – Vol. 110 (6). – P. 783-787.188. Evolution in endometrial cancer: evidence from an immunohistochemicalstudy / I. Vandenput [et al.] // Int. J. Gynecol. Cancer. – 2011. – Vol. 21 (2). – P. 316322.189. Ewies, A.A. Managing postmenopausal bleeding revisited: what is the bestfirst line investigation and who should be seen within 2 weeks? A cross-sectional studyof 326 women / A.A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
